12/30/2023 0 Comments Medical device recent iposAnnounces Positive Interim Data from the Phase IIb Expansion Cohort of ASC22 (Envafolimab) for Chronic Hepatitis B Functional CureĪscletis Enrolls 120 Patients in Phase 3 Clinical Trial for Combination Treatment for Glioblastoma Shares Fall 6%Īscletis Pharma Inc. Announces Initiation of Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of AcneĪscletis Pharma Presents Data on Studies for Liver Treatments at US Liver Disease MeetĪscletis Pharma Publishes Results of Gannex's Fatty Liver MedicationĪscletis Pharma Presents Data in Germany from Phase 2 Study on Anti-Acne DrugĪscletis Pharma Finds Envafolimab Safe to Use in StudyĪscletis Pharma Inc. The most advanced drug candidates include ASC22 (HBV functional cure), ASC10 and ASC11(oral small molecules for COVID-19 treatment), ASC40 (recurrent glioblastoma), ASC42 (PBC, primary biliary cholangitis), and ASC40 (acne).įor more information, please visit View original content: Īscletis Pharma Gets Nod to Trial Acne DrugĪscletis Pharma Inc. ritonavir tablets, GANOVO ® and ASCLEVIR ®, and 23 drug candidates in its R&D pipeline. To date, Ascletis has three marketed products, i.e. Through excellent execution, Ascletis rapidly advances its drug pipeline with an aim of leading in global competition. Led by a management team with deep expertise and a proven track record, Ascletis focuses on three therapeutic areas with unmet medical needs from a global perspective: viral diseases, non-alcoholic steatohepatitis (NASH) and oncology. We will continue to advance the clinical development of our pipeline assets to benefit more patients."Īscletis is an innovative R&D driven biotech listed on the Hong Kong Stock Exchange (1672.HK), covering the entire value chain from discovery and development to manufacturing and commercialization. Wu, Founder, Chairman and CEO of Ascletis, " This year, we expect to announce multiple clinical readouts from Phase II studies of ASC40 (acne), ASC41(NASH), ASC22 (HBV), ASC40 (NASH) and ASC10 (RSV). The inclusion of Ascletis as a constituent stock of the HSHKBIO demonstrates the capital market's recognition of and confidence in our business and development prospects." said Dr. "We extend our gratitude to investors for their great support. HSHKBIO reflects the overall performance of the biotech companies that are listed in Hong Kong, including stocks listed through the Listing Rules Chapter 18A of Hong Kong Exchange. HSHKBIO selects securities of multiple listed companies in the category of pharmaceuticals, biotechnology or medical devices from the sub-categories of the Hang Seng Industry Classification System as the index sample. (HKEX: 1672, "Ascletis") announces today that it will be included in the Hang Seng Hong Kong-Listed Biotech Index (Index code: HSHKBIO), effective from March 13, 2023. 27, 2023 /PRNewswire/ - Ascletis Pharma Inc.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |